Supposedly both Novartis and Shire may be leading candidates to buy Belgium-based eye company ThromboGenics. Morgan Stanley is said to be leading the way in discussions towards this end. Also rumored to be on the fringes are Valeant Pharmaceuticals, Regeneron Pharmaceuticals, and Allergan. Needless to say, ThromboGenics price has gone up 17% today on the news. None of the possible suitors mentioned above had any comments on this report.
ThromboGenics best selling drug is Jetrea, and Novartis currently has marketing rights for it outside the US. The drug also complements another Novartis eye drug, Lucentis. Analysts consider Novartis the front runner in this rumored chase -- but again it is only a rumor at this juncture -- and may not be everything that meets the eye. See Bloomberg report.
Posted by Bruce Lehr April 14th 2014.